← Назад к работе
Работы, на которые ссылается эта работа
Работ: 77
Работа: Protective Potential of Sodium-Glucose Cotransporter 2 Inhibitors in Internal Medicine (Part 1)
Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure
Milton Packer, Stefan D. Anker, Javed Butler +36
Статья2020Цитирований: 4ABIDapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
John J.V. McMurray, Scott D. Solomon, Silvio E. Inzucchi +35
Статья2019Цитирований: 3ABIEmpagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Bernard Zinman, Christoph Wanner, John M. Lachin +9
Статья2015Цитирований: 2ABIDapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
Stephen D. Wiviott, Itamar Raz, Marc P. Bonaca +17
Статья2018Цитирований: 2ABIDapagliflozin in Patients with Chronic Kidney Disease
Hiddo J.L. Heerspink, Bergur V. Stefánsson, Ricardo Correa‐Rotter +11
Статья2020Цитирований: 2ABIKEAP1‐NRF2 protein–protein interaction inhibitors: Design, pharmacological properties and therapeutic potential
Enrique Crisman, Pablo Duarte, E. Daudén +4
Обзорная статья2022Цитирований: 2ABIA Comprehensive Guide to Sodium Glucose Cotransport Inhibitors
Christopher Cunningham, Ahmad Jabri, Laith Alhuneafat +1
Обзорная статья2023Цитирований: 2ABICardiovascular prevention 2022. Russian national guidelines
S. А. Boytsov, Nana Pogosova, А. А. Аншелес +34
Статья2023Цитирований: 2ABIPharmacovigilance study for SGLT 2 inhibitors- Safety review of real-world data & randomized clinical trials
Karan B. Bhanushali, Heena Asnani, Ambica Nair +2
Обзорная статья2024Цитирований: 2ABI